about
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaSunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trialsPrognosis of pN3 stage gastric cancer.Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.Povidone-iodine for the management of oral mucositis during cancer therapy.PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisConcordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors.Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneEstablishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationIndoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinomaNeoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rateImmunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future PerspectivesTargeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerYH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerMolecular characterization of lung adenocarcinoma from Korean patients using next generation sequencingRecurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case ReportRepotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung CancerA phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIsReal-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung CancerPatient-Derived Cells to Guide Targeted Therapy for Advanced Lung AdenocarcinomaHigh CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinomaComprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practiceDynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapyHyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerImpact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung CancerPredictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitorsAntitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
P50
Q33385981-6C4B8DD1-C289-45EC-9A5B-58581238EA7CQ33396613-C130AF47-9D0F-4E72-942C-C8B6084900E2Q33576276-0C1AB663-3F86-4A4B-8985-EF9FDB988AD9Q37316735-F8088377-B301-45B6-BF70-54427A1A1FC7Q38705330-96097470-3616-4BCF-ADB3-E1965BEBA0F3Q41676886-95580050-8589-4B0A-AFF6-086249C28587Q42369181-7C2037C4-F6D9-4827-9FF3-4ACA6A20F7D9Q42371507-230827E8-25E1-4400-8236-347E96CFB961Q46178018-1F5CE277-54F4-4429-B2E4-C6A06A798975Q47433338-B90F660C-506B-41A8-8E2B-31A992B1BFB1Q48651245-354C001E-7983-4EBC-B3E6-E1EA86A4BC54Q52718501-F5EBEEF0-0D5C-46F8-A2CD-6B63352EBC5FQ54976677-7B198216-A993-494B-A383-DA706064DC6AQ54977364-2354B23E-EFE1-42F7-B3C3-B726A0496EDFQ57222268-59BAE353-D9F7-4297-8982-F99B6A69D9D8Q60683127-B2FDEA94-29DE-48AD-8506-01D89D71CACCQ64110138-F0D2FFA7-5985-4C77-91DE-1EE3249F4228Q64121064-A9AE5DB3-4048-4AB9-9B45-3730A26F2CBCQ90220124-BA66E77C-22E4-4209-81F5-FFAF334CF60BQ90842548-35209297-E1F2-4246-9BAB-4CD62D767919Q91167440-F5B712AE-1586-49D0-9E23-2FB2EC43D24CQ91439199-ED9BD3DB-286A-4068-B23E-2FCECC765A62Q91508230-6E57BF88-84C2-4122-ACA5-4CA88BF3242EQ91737484-67B9D32A-685D-4B42-9E79-BD4DB0D3898BQ91998018-FF76B908-8B89-4249-97C5-D3D3D5AA38D0Q92263247-A4494B9C-B300-4498-A18F-DF0D5CD1522BQ92287962-ABDD6CA3-1FB1-40A2-A32D-06089EB95EE0Q92289777-9B32A6E7-B704-4049-A7B1-75374FAE336AQ92619000-F52FF66A-DFA6-469B-8920-0066C5CD2655Q92672121-259074AC-5247-42E4-9055-F5D558BE5365Q93052800-017F4E3B-C677-4DB1-BDD1-736C5E7885CCQ93056401-DB3DD87B-7B01-4B23-BF66-E56F925AAC4BQ93093196-328884EA-2C41-4F10-8353-44563D55929DQ94947874-7581B4D2-676E-4C15-A50F-3E4C6BC2FAE9
P50
description
researcher ORCID ID = 0000-0003-3490-2195
@en
wetenschapper
@nl
name
Min Hee Hong
@ast
Min Hee Hong
@en
Min Hee Hong
@es
Min Hee Hong
@nl
type
label
Min Hee Hong
@ast
Min Hee Hong
@en
Min Hee Hong
@es
Min Hee Hong
@nl
prefLabel
Min Hee Hong
@ast
Min Hee Hong
@en
Min Hee Hong
@es
Min Hee Hong
@nl
P106
P1153
57191958755
P31
P496
0000-0003-3490-2195